These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

589 related items for PubMed ID: 27638739

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease.
    Farkas K, Molnár T.
    Immunotherapy; 2018 Feb; 10(2):107-117. PubMed ID: 29124994
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Progress with infliximab biosimilars for inflammatory bowel disease.
    Kurti Z, Gonczi L, Lakatos PL.
    Expert Opin Biol Ther; 2018 Jun; 18(6):633-640. PubMed ID: 29688797
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparative effectiveness of the biosimilar CT-P13.
    Yoo DH.
    J Comp Eff Res; 2017 Nov; 6(8):693-712. PubMed ID: 29172717
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Analysis of clinical trials of biosimilar infliximab (CT-P13) and comparison against historical clinical studies with the infliximab reference medicinal product.
    Yoo DH, Oh C, Hong S, Park W.
    Expert Rev Clin Immunol; 2015 Nov; 11 Suppl 1():S15-24. PubMed ID: 26395833
    [Abstract] [Full Text] [Related]

  • 11. Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe.
    Müller-Ladner U, Hong S, Oh C, Taylor P.
    Expert Rev Clin Immunol; 2015 Nov; 11 Suppl 1():S5-14. PubMed ID: 26395832
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. CT-P13 in the treatment of rheumatoid arthritis.
    Yoo DH.
    Expert Rev Clin Immunol; 2017 Jul; 13(7):653-666. PubMed ID: 28571501
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Biosimilars in the therapy of inflammatory bowel diseases.
    Hlavaty T, Letkovsky J.
    Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):581-7. PubMed ID: 24722561
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.